- Partnership to focus on implementing a medical product
development strategy for VIVO's global medical cannabis offering,
utilizing CB2 Insights' leading technology platform Sail and
research capabilities
- Joint venture will aim to increase the collection of real word
data to assist health care stakeholders in making informed
decisions on new cannabis-based treatments for patients
- In collaboration, VIVO and CB2 Insights will look to uncover
data trends and insights from Canada that will help inform ventures in the
international marketplace
TORONTO, Oct. 29, 2019 /CNW/ - CB2 Insights Inc.
(CSE:CBII; OTCQB: CBIIF) ("CB2"), a leading data-driven company
focused on bringing real-world evidence driven from the
point-of-care to the medical cannabis community, announced it has
entered into a technology and multi-phase research agreement with
VIVO Cannabis Inc. (TSX-V: VIVO, OTCQX: VVCIF) ("VIVO"), an
Ontario-based cannabis company
recognized for its premium products and services, to assist in the
development of VIVO's global medical product development
strategy.
Under the terms of the agreement, CB2 will be integrating CB2's
Clinical Data Management Software (CDMS) and Electronic Data
Capture (EDC) tools to establish better understanding of VIVO's
current medical patient registry. Concurrently, the two companies
will collaborate on a comprehensive multi-phase research strategy
that will validate the safety and efficacy of current products. The
plan is ultimately expected to help inform the design of clinical
trials to support the deployment of future cannabis-based
medicines.
"As the industry continues to evolve, regulatory bodies are
putting greater emphasis on the validation of cannabis-based
treatments through clinical trial data to measure their safety and
efficacy," said Prad Sekar, CEO of CB2. " We will work closely with
the team at VIVO to design a research strategy backed by the
collection of high-quality real world clinical data to support
their current and future product innovations."
"CB2's global experience in clinical research and technology
will enable VIVO to enhance our understanding of Canadian medical
patients. This will facilitate our uncovering of new ways to meet
the expectations of our current patients and will help inform our
international growth plans," said Barry
Fishman, CEO of VIVO. "At VIVO, our purpose is to help
patients achieve a positive quality of life with cannabis. We look
forward to utilizing our partnership with CB2 to further bring real
world evidence to the medical cannabis industry."
About CB2 Insights
CB2 Insights (CSE:CBII) is a global leader in clinical
operations, technology & analytics solutions and research and
development services, with a mission to mainstream medical cannabis
into traditional healthcare. Providing immediate market access
through its wholly-owned clinical network across 12 jurisdictions,
proprietary data-driven technology solutions and comprehensive
contract research services designed for those in both the medical
cannabis and traditional life sciences industries, CB2 Insights is
able to support its partners across the entire data and research
spectrum.
CB2's Clinical Operations business unit leverages extensive
experience to develop clinical models with standard operating
procedures, advanced workflows, training and ongoing management
support. CB2 also owns and operates its own speciality clinics
including the brands Canna Care Docs and Relaxed Clarity, which
assess nearly 100,000 patients seeking medical cannabis treatment
to provide immediate market access to US-based product
manufacturers for clinical trial and research programs.
CB2 has built both electronic data capture (EDC) and clinical
data management software (CDMS) which work to support its partners
of any size to execute their data and clinical strategies.
CB2 also offers comprehensive contract research organization
(CRO) services including full scale clinical trial management,
trial design, monitoring and other key research functions used by
licensed producers, multi-state operators and traditional
pharmaceutical companies entering the medical cannabis space.
For more information please visit www.cb2insights.com.
About VIVO Cannabis™
VIVO, based in Napanee, Ontario, is recognized for trusted, premium
cannabis products and services. It holds production and sales
licenses from Health Canada and operates world-class indoor
cultivation facilities with proprietary plant-growing technology at
its Canna Farms facility in Hope, B.C., and at its Vanluven
facility in Napanee, Ontario.
VIVO has a collection of premium brands targeting unique customer
segments, including Beacon Medical™, Fireside™, Canna Farms™ and
Lumina™. The Company is significantly expanding its production
capacity and distribution channels; growing its domestic medical
cannabis platform, including Harvest Medicine, its patient-centric,
highly scalable network of specialty medical cannabis clinics and
services; promoting production and cultivation innovation and
pursuing partnership and product development opportunities; and
actively focusing on growth in select international markets,
including Germany and Australia. VIVO has a healthy
balance sheet and is well-positioned to accelerate its growth
in Canada and internationally. For more information
visit: www.vivocannabis.com
Forward Looking Statements
Statements in this news release that are forward-looking
statements are subject to various risks and uncertainties
concerning the specific factors disclosed here and elsewhere in
filings of CB2 and VIVO with Canadian securities regulators. When
used in this news release, words such as "will, could, plan,
estimate, expect, intend, may, potential, believe, should," and
similar expressions, are forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding the expected benefits of the partnership
between CB2 and VIVO, and their expected research focus.
Although CB2 and VIVO have attempted to identify important
factors that could cause actual results, performance or
achievements to differ materially from those contained in the
forward-looking statements, there can be other factors that cause
results, performance or achievements not to be as anticipated,
estimated or intended, including, but not limited to: failure to
agree or on, or implement, propopsed strategies; failure of the
research programs to be undertaken to yield the expected data and
results; changes in laws; reliance on management; requirements for
additional financing; competition; hindering market growth and
state adoption due to inconsistent public opinion and perception of
the medical-use and recreational-use cannabis industry and;
regulatory or political change.
There can be no assurance that such information will prove to
be accurate or that management's expectations or estimates of
future developments, circumstances or results will materialize. As
a result of these risks and uncertainties, the results or events
predicted in these forward-looking statements may differ materially
from actual results or events.
Accordingly, readers should not place undue reliance on
forward-looking statements. The forward-looking statements in this
news release are made as of the date of this release. CB2 and VIVO
disclaim any intention or obligation to update or revise such
information, except as required by applicable law, and CB2 and VIVO
do not assume any liability for disclosure relating to any other
company mentioned herein.
The Canadian Securities Exchange, TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the either Exchange) accepts
responsibility for the adequacy or accuracy of this
release
SOURCE VIVO Cannabis Inc.
